Efficacy and safety of the first made in Russia alpha, beta long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree
Copyright policy )Efficacy and safety of the first made in Russia alpha, beta long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree
Aim. To study efficacy and safety of a new dose and dosage form of proxodolol - a beta-adrenoblocker with alpha1-adrenoblocking activity - in patients with moderate arterial hypertension (AH). Material and methods. A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n = 40) received proxodolol, group 2 (n = 20) was given carvedilol. The trial lasted for 89 days. Results. The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH. Conclusion. Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
proxodolol, arterial hypertension, beta-adrenoblockers, R, Medicine, carvedilol
proxodolol, arterial hypertension, beta-adrenoblockers, R, Medicine, carvedilol
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!